# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes

Study · id `cardio:ct-nct07901595` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07901595](<https://clinicaltrials.gov/study/NCT07901595>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07901595

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 147 participants.

## Technical summary

Registry record NCT07901595. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2027-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 147 participants (planned count; ClinicalTrials.gov record NCT07901595, source copy `cardio:ctgov-nct07901595-2026-10-28`, retrieved 2026-10-31)
- Planned start: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT07901595, source copy `cardio:ctgov-nct07901595-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2027-11-01 (anticipated) (ClinicalTrials.gov record NCT07901595, source copy `cardio:ctgov-nct07901595-2026-10-28`, retrieved 2026-10-31)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07901595, source copy `cardio:ctgov-nct07901595-2026-10-28`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07901595-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
- Condition: Healthy Volunteers and Diabetes Participants
- Intervention (Drug): PAL-119
- Intervention (Drug): Placebo
- Lead sponsor: Paulex Bio Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 423758ebf1ef726a270a477f69ef50026db3e51ebd06ac96c3bd691f70aceab6
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
